Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Co. is applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms. Each platform has several programs: Cerebrum, which is a small molecule platform, utilizing understanding of neuronal excitability and neuronal networks; and Solidus (antisense oligonucleotide), which is medicine discovery and development engine anchored on a proprietary, computational methodology. The PRAX average annual return since 2020 is shown above.
The Average Annual Return on the PRAX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PRAX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRAX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|